Chapter 39 : Rationalizing Vaccination

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Rationalizing Vaccination, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817442/9781555815004_Chap39-1.gif /docserver/preview/fulltext/10.1128/9781555817442/9781555815004_Chap39-2.gif


The new prospects for immunization against a greatly extended portfolio of infections, and against cancers, point to a transformation in medicine far more extensive than the “antibiotic revolution” of the past. Drugs and vaccines have, of course, long been complementary approaches in controlling infectious diseases. Many antibiotics are declining in potency, just as the extreme crudity of an approach that kills commensal organisms, as well as intended targets is realized. As Columbia University public health specialist Jane Sisk and colleagues observed in the , immunization to prevent pneumococcal bacteremia in elderly people is one of the few interventions that both improves patient well-being and saves medical costs. It is, however, the wide variety of emerging vaccines that illustrates the full scale of the transformation likely in the years ahead. One of the most heartening developments during recent years has been the discovery that certain new vaccines, previously validated in industrialized countries, have also been effective in parts of the world where poor nutrition and other problems might have rendered them less powerful. The ultimate step is the comprehensive identification of all genes associated with virulence and antigenicity through the sequencing of pathogens. Finally, the burgeoning revolution in vaccinology is surely the moment to coordinate our use of these potent prophylactics internationally. It makes little sense, for example, that virtually every member country of the European Union has a different policy or reimbursement schedule for influenza vaccination.

Citation: Dixon B. 2009. Rationalizing Vaccination, p 179-183. In Animalcules. ASM Press, Washington, DC. doi: 10.1128/9781555817442.ch39
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Chang, M.-H.,, C. J. Chen,, M. S. Lai,, H. M. Hsu,, T. C. Wu,, M. S. Kong,, D. C. Liang,, W. Y. Shau,, and D. S. Chen. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336: 1855 1859.
2. Frisch, M.,, B. Glimelius,, A. J. C. van den Brule,, J. Wohlfahrt,, C. J. L. M. Meijer,, J. M. M. Walboomers,, S. Goldman,, C. Svensson,, H.-O. Adami,, and M. Melbye. 1997. Sexually transmitted infection as a cause of anal cancer. N. Engl. J. Med. 337: 1350 1358.
3. Kahn, J. A.,, and R. D. Burk. 2007. Papillomavirus vaccines in perspective. Lancet 369: 2135 2137.
4. Katz, S. L. 1997. Future vaccines and a global perspective. Lancet 350: 1767 1770.
5. Linhares, A. C.,, F. R. Velázquez,, I. Pérez-Schael,, X. Sáez-Llorens,, H. Abate,, F. Espinoza,, P. López,, M. Macías-Parra,, E. Ortega-Barría,, D. M. Rivera-Medina,, L. Rivera,, N. Pavía-Ruz,, E. Nuñez,, S. Damaso,, G. M. Ruiz-Palacios,, B. De Vos,, M. O'Ryan,, P. Gillard,, A. Bouckenooghe, and the Human Rotavirus Vaccine Study Group. 2008. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 371: 1181 1189.
6. Sisk, J. E.,, A. J. Moskowitz,, W. Whang,, J. D. Lin,, D. S. Fedson,, A. M. McBean,, J. F. Plouffe,, M. S. Cetron,, and J. C. Butler. 1997. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278: 1333 1339.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error